Navigation Links
Jharkhand Ropes in Private Players for Health Scheme

In a unique public-private partnership in healthcare, the Jharkhand government has set up a trust that will ensure medical care for the poor that will be partly funded// by private investors in the state.

The Sarva Swasthya Mission Trust is the brainchild of Chief Minister Arjun Munda who has roped in major investors to provide funds. He has also mooted a proposal for a health card for poor families.

"Private investors like the Tata Group, Essar, Jindal group and others have assured to contribute to the trust to help the poor," said a government official.

"The Tata group has assured to give Rs.250 million per year for a period of 30 years. The other groups will also contribute handsome amounts."

The trust aims to reach out to people in the rural areas of the state and help the poor, particularly the below poverty line (BPL) families, to get access to affordable and good quality medical services.

The percentage of BPL families in Jharkhand is 52 percent.

(Source: IANS)
'"/>




Page: 1

Related medicine news :

1. Jharkhand reports 13,000 Malaria cases
2. Jharkhand To Have Mobile Hospital
3. Jharkhand Gives Health industry status
4. Jharkhand Pharmacies Refuse To Sell Viagra
5. Jharkhand Chemists to Boycott Viagra
6. Yoga Guru Ramdev Invited to Tap Ayurveda Potential by Jharkhand Govt
7. Ramdev Signs MOU With Jharkhand Govt To Set Up Ayurveda Hospital
8. Jharkhand Govt Tie Up With Ramdev To Preserve Rare Herbal Plants
9. Jharkhand To Host Chicken Festival
10. Jharkhand Faces Acute Shortage Of Life-saving Drugs
11. Druggists On Strike In Jharkhand To Protest Against VAT Anomalies
Post Your Comments:
(Date:10/8/2008)... , Dr. Robert Bernstein, ...rocedure for hair restoration is featured on the O...atment. , New York, NY (P...atures Dr. Bernstein discussing his pioneering fol...n the newest diagnostic and treatment techniques f...
(Date:10/7/2008)... U.S. recommendations reflect previously publ...LAS, Oct. 7 /PRNewswire-USNewswire/ -- Guidelines,...epartment of Health and,Human Services (HHS) were ...ts Medicine (ACSM) and the American Heart Associat...hed physical activity recommendations,last year, a...
(Date:10/7/2008)ANAHEIM, Calif., Oct. 7 /PRNewswire-USNewswire/ -- CHADD, the nation,s,largest organization serving people affected by AD/HD, will hold its Annual,International Conference on AD/HD November 12-1
(Date:10/7/2008)... Compression ultrasound similar to more expensive... , TUESDAY, Oct. 7 (HealthDay News) -- An o...leg -- called deep vein thrombosis, or DVT -- is a...esearch says. , European researchers found that...alled compression or duplex ultrasound -- was as g...
Breaking Medicine News(10 mins):Health News:Pioneering Hair Transplant Doctor Explains Procedure on Oprah Winfrey Show 2Health News:ACSM, AHA Support Federal Physical Activity Guidelines 2Health News:ACSM, AHA Support Federal Physical Activity Guidelines 3Health News:Simpler Test May Be Best for Diagnosing Blood Clots in Leg 2Health News:Simpler Test May Be Best for Diagnosing Blood Clots in Leg 3
...are commonly used for a number of painful complai... attack and stroke//. This has lead to an order by...rugs will have to carry a warning along with the i...turers. Doctors are being informed of the small ...
...nt study, women with a twin are at upto 5 times hi...an those without one//. The study was conducted o... The risk of premature ovarian failure (POF) at th...s than women from the general population. POF caus...
...lie Minogue with breast cancer has led to confusio...o get breast cancer//. Cancer Research UK said t...re likely to strike the under-70s than women over ...en revealed that 77 per cent of them thought that ...
...safe for administration in babies and toddlers, re...of flu shots//. Two flu seasons back, the federal...the age 6 months to 2 years and their family membe...ise in the number of children getting vaccinated. ...
Other Medicine News:
(Date:10/7/2008)... VIENNA, Va., Oct. 7 /...y that it has entered into a Material Transfer,Agr...h Clinical Center,(NIHCC) and the laboratory of Dr... molecular basis of changes to the tumor microenvi... Dr. Marincola is the Chief of,the Infectious Dise...
(Date:10/7/2008)... - Data Presented Today at ACG Annual Sc...wire-FirstCall/ -- Ironwood,Pharmaceuticals, Inc. ...,Inc. (NYSE: FRX ) today announced the presentati...clotide,s safety and efficacy in 420 patients with...). Analysis of the data,indicates that once- daily...
(Date:10/7/2008)... Several abstracts highlighting CIMZIA,s long...hn,s disease patients presented at American Colleg... /- Data from two studies,p...of Gastroenterology,(ACG) Annual Meeting demonstra...PEGylated anti-TNF alpha (Tumor Necrosis Factor al...
(Date:10/7/2008)... - Planned 15 Patient Cohort Enrolled in Stage A...ombination With Carboplatin and Paclitaxel -, TUS...grine,Pharmaceuticals, Inc. (Nasdaq: PPHM ), a cl...monoclonal antibodies for the treatment of cancer ...nced that it has completed,enrollment in the first...
Breaking Medicine Technology:CEL-SCI Enters Agreement With National Institutes of Health Clinical Center To Determine the Molecular Basis of Multikine Anti-Tumor Effect 2CEL-SCI Enters Agreement With National Institutes of Health Clinical Center To Determine the Molecular Basis of Multikine Anti-Tumor Effect 3Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation 2Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation 3Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation 4Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation 5CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 2CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 3CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 4CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 5CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 6CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 7CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 8CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 9Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Its Second Bavituximab Phase II Breast Cancer Trial 2Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Its Second Bavituximab Phase II Breast Cancer Trial 3Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Its Second Bavituximab Phase II Breast Cancer Trial 4Doctors See How Cancer Drug Can Damage Kidneys 14210 1Doctors See How Cancer Drug Can Damage Kidneys 14210 2Doctors See How Cancer Drug Can Damage Kidneys 14210 3New Tools Boost Alzheimers Awareness 14206 1New Tools Boost Alzheimers Awareness 14206 2New Tools Boost Alzheimers Awareness 14206 3WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results 3916 1WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results 3916 2WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results 3916 3WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results 3916 4WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results 3916 5WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results 3916 6WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results 3916 7WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results 3916 8WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results 3916 9WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results 3916 10WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results 3916 11WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results 3916 12The Makers of Conquer HA 28TM 29 Launch All Natural Double Strength Anti Inflammatory Formula 14200 1The Makers of Conquer HA 28TM 29 Launch All Natural Double Strength Anti Inflammatory Formula 14200 2
...a national reference laboratory and a worldwide le...ment. ARUP offers an extensive test menu of highly...anatomic pathology. Owned by the University of Uta...lf of the nation's university teaching hospitals a...
...a national reference laboratory and a worldwide le...ment. ARUP offers an extensive test menu of highly...anatomic pathology. Owned by the University of Uta...lf of the nation's university teaching hospitals a...
...a national reference laboratory and a worldwide le...ment. ARUP offers an extensive test menu of highly...anatomic pathology. Owned by the University of Uta...lf of the nation's university teaching hospitals a...
...a national reference laboratory and a worldwide le...ment. ARUP offers an extensive test menu of highly...anatomic pathology. Owned by the University of Uta...lf of the nation's university teaching hospitals a...
Medicine Products: